Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 8Breast Neoplasms 6Prostatic Neoplasms 5Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Lung Neoplasms 2Glioma 2Glioblastoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 1niraparib 1liposomal doxorubicin 1cemiplimab 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hereditary Sensory and Autonomic Neuropathies × niraparib × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡